About the discrepancies between consensus documents, clinical practice guidelines, and legal regulations in the treatment of type 2 diabetes

Nefrologia

Volumn 32, Issue 6, 2012, Pages 835-837

  Martínez Castelao, Alberto ^a   Górriz, José L ^b   Sola, Eva ^b   Morillas, Carlos ^b   Jover, Ana ^b   Coronel, Francisco ^c   Navarro González, Juan ^d   de Álvaro, Fernando ^e  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^e HOSPITAL UNIVERSITARIO INFANTA SOFÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84873736501     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: 10.3265/Nefrologia.pre2012.Oct.11731     Document Type: Letter

References (11)

1. Serra-Tarragón J. Antidiabéticos en insuficiencia renal crónica; nuevas preguntas a nuevos y clásicos fármacos. Nefrologia 2012;32(6):835
2. Martínez-Castelao A, Górriz JL, Sola E, Morillas C, Jover A, Coronel F, et al. A propósito de las discrepancias entre documentos de consenso, guías de práctica clínica y normativa legal en el tratamiento de la diabetes tipo 2. Nefrologia 2012;32(4):419-26.
3. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(2 Suppl 1):S1-266.
4. Eckardt KU, Berns JS, Rocco MV, Kasiske BL. Definition and classification of CKD: the debate should be about patient prognosis-a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009;53:915-20.
5. Stevens LA, Nolin TD, Richardson MM, Feldman HI, Lewis JB, Rodby R, et al. Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations. Am J Kidney Dis 2009;54:33-42.
6. Lobowsky ND, Siegel R, Pittas G. Management of glycemia in patients with diabetes mellitus and CKD. Am J Kidney Dis 2007;50:865-79.
7. Product monograph: Glucobay™. Acarbose. Available at: http://www.bayer.ca/files/GLUCOBAYPM-ENG-10JUN2010-137275-rev1.pdf
8. ACCORD, The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545-59.
9. Skyler JS, Bergenstal R, Bonow RO, Buse J, Deedwania P, Gale EA, et al.; American Diabetes Association; American College of Cardiology Foundation; American Heart Association. et al. Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Circulation 2009;119:351-7.
10. Mehrotra R, Kalantar-Zadeh K, Adler S. Assessment of glycemic control in dialysis patients with diabetes: glycosylated hemoglobin or glycated albumin?. Clin J Am Soc Nephrol 2011;6:1520-2.
11. Matzke GR, Aronoff GR, Atkinson AJ Jr, Bennett WM, Decker BS, Eckardt KU, et al. Drug dosing consieration in patients with acute and chronic kidney disease-a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2011;80:1122-37.